4.6 Article

Erectile dysfunction

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 2, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrdp.2016.3

关键词

-

资金

  1. Ferring
  2. Bayer
  3. ESSM
  4. ISSM
  5. Besins
  6. Otsuka
  7. Eli-Lilly
  8. Menarini
  9. Prostrakan
  10. Intercept
  11. Pfizer
  12. Lilly
  13. CIACT
  14. NIH
  15. SMSNA
  16. American Medical Systems

向作者/读者索取更多资源

Erectile dysfunction is a multidimensional but common male sexual dysfunction that involves an alteration in any of the components of the erectile response, including organic, relational and psychological. Roles for nonendocrine (neurogenic, vasculogenic and iatrogenic) and endocrine pathways have been proposed. Owing to its strong association with metabolic syndrome and cardiovascular disease, cardiac assessment may be warranted in men with symptoms of erectile dysfunction. Minimally invasive interventions to relieve the symptoms of erectile dysfunction include lifestyle modifications, oral drugs, injected vasodilator agents and vacuum erection devices. Surgical therapies are reserved for the subset of patients who have contraindications to these nonsurgical interventions, those who experience adverse effects from (or are refractory to) medical therapy and those who also have penile fibrosis or penile vascular insufficiency. Erectile dysfunction can have deleterious effects on a man's quality of life; most patients have symptoms of depression and anxiety related to sexual performance. These symptoms, in turn, affect his partner's sexual experience and the couple's quality of life. This Primer highlights numerous aspects of erectile dysfunction, summarizes new treatment targets and ongoing preclinical studies that evaluate new pharmacotherapies, and covers the topic of regenerative medicine, which represents the future of sexual medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据